EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudie

Efficacy and Safety of Levofloxacin‐ Versus Moxifloxacin‐Based Nitazoxanide Quadruple Therapy as Second‐Line Treatment for Helicobacter pylori in Egypt: A Randomized Multicenter Trial

Gasser El-Azab iD, Sherief Abdel Salam iD, Ehab Moustafa iD, Ahmed Abuoelhassan iD, Ayman Shamseya iD, Ahmed Ellakany iD, Usama Abdelaal iD, Medhat Assem iD, Fatma Khalil iD, Amal Mahmoud iD, Maha Elsabaawy iD, Boshra Hussein iD und 4 weitere

Helicobacter · 2026

DOI: 10.1111/hel.70104 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Helicobacter, 2026. Verfasst von Gasser El-Azab und 15 weiteren Autor:innen. Beteiligte Einrichtung: Hepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Menoufia, Egypt. Hauptthemen laut MEDLINE: Helicobacter Infections, Levofloxacin, Moxifloxacin, Anti-Bacterial Agents. Die Arbeit nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Eradication of Helicobacter pylori remains challenging in countries with high antimicrobial resistance and limited access to bismuth‐based therapies. Quinolone‐containing regimens represent a practical alternative, yet comparative data between levofloxacin‐ and moxifloxacin‐based nitazoxanide quadruple therapies are scarce, particularly in Egypt. This multicenter trial evaluated the efficacy, safety, and tolerability of two nitazoxanide‐based second‐line regimens after failure of first‐line eradication therapy.

Methods

In this prospective, randomized, single‐blind, parallel‐group study conducted at six Egyptian centers, adults aged 18–70 years with documented failure of first‐line H. pylori therapy were enrolled. Patients were randomized 1:1 to receive either LNDL (levofloxacin 750 mg once daily, nitazoxanide 500 mg twice daily, doxycycline 100 mg twice daily, lansoprazole 30 mg twice daily) or MNDL (moxifloxacin 400 mg once daily with the same adjunct medications) for 14 days. Eradication was assessed using a stool antigen test ≥ 4 weeks after treatment. Safety, tolerability, and symptom improvement were recorded. Analyses were performed using both intention‐to‐treat (ITT) and per‐protocol (PP) populations.

Results

A total of 430 patients were randomized. ITT eradication rates were 65.6% (95% CI: 59.2% – 72%) for LNDL and 74.9% (95% CI: 69% – 80.7%) for MNDL ( p = 0.035). PP eradication rates were 70.9% (95% CI: 64.5% – 77.2%) and 78.5% (95% CI: 72.9% – 84.2%), respectively ( p = 0.076). Among patients previously treated with levofloxacin, MNDL achieved significantly higher eradication rates than LNDL (65.8%, 95% CI: 50–81.6 vs. 42.6%, 95% CI: 29–56.2, p = 0.028). Both regimens produced significant symptom improvement and were well tolerated; no serious adverse events occurred.

Conclusion

Both nitazoxanide‐based quinolone quadruple regimens demonstrated modest but clinically relevant efficacy as second‐line therapy. Moxifloxacin showed superior performance in patients with prior levofloxacin exposure. These findings support the use of moxifloxacin‐based rescue therapy in settings with high resistance and limited access to bismuth‐containing regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsLevofloxacinMoxifloxacinAnti-Bacterial AgentsHelicobacter pyloriThiazolesHumansMiddle AgedAdultFemaleMaleEgyptAgedDrug Therapy, CombinationTreatment OutcomeYoung AdultProspective StudiesAdolescentNitro CompoundsSingle-Blind Method

Stichwörter der Autor:innen

Helicobacter pylorieradicationlevofloxacinmoxifloxacinnaïvenitazoxanidequinolonesresistance

Substanzen

nitazoxanideLevofloxacinMoxifloxacinAnti-Bacterial AgentsThiazolesNitro Compounds

Autor:innen und Institutionen

  • Hepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Menoufia, Egypt.
  • Tropical Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
  • Tropical Medicine and Gastroenterology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
  • Gastroenterology, Hepatology and Infectious Diseases, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
  • Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.
  • Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, Sohag University, Sohag, Egypt.

ORCID-Profile: Gasser El-Azab, Sherief Abdel Salam, Ehab Moustafa, Ahmed Abuoelhassan, Ayman Shamseya, Ahmed Ellakany, Usama Abdelaal, Medhat Assem, Fatma Khalil, Amal Mahmoud, Maha Elsabaawy, Boshra Hussein, Mohammed Ezz-Eldin, Sahar Hassany, Nariman Zaghloul, Mai Magdy

Zitieren

APA

El-Azab, G., Abdel Salam, S., Moustafa, E., Abuoelhassan, A., Shamseya, A., Ellakany, A., Abdelaal, U., Assem, M., Khalil, F., Mahmoud, A., Elsabaawy, M., Hussein, B., Ezz-Eldin, M., Hassany, S., Zaghloul, N., & Magdy, M. (2026). Efficacy and Safety of Levofloxacin‐ Versus Moxifloxacin‐Based Nitazoxanide Quadruple Therapy as Second‐Line Treatment for Helicobacter pylori in Egypt: A Randomized Multicenter Trial. Helicobacter. https://doi.org/10.1111/hel.70104

Vancouver

El-Azab G, Abdel Salam S, Moustafa E, Abuoelhassan A, Shamseya A, Ellakany A, et al. Efficacy and Safety of Levofloxacin‐ Versus Moxifloxacin‐Based Nitazoxanide Quadruple Therapy as Second‐Line Treatment for Helicobacter pylori in Egypt: A Randomized Multicenter Trial. Helicobacter. 2026. doi:10.1111/hel.70104

BibTeX
@article{ElAzab2026,
  author = {El-Azab, Gasser and Abdel Salam, Sherief and Moustafa, Ehab and Abuoelhassan, Ahmed and Shamseya, Ayman and Ellakany, Ahmed and Abdelaal, Usama and Assem, Medhat and Khalil, Fatma and Mahmoud, Amal and Elsabaawy, Maha and Hussein, Boshra and Ezz-Eldin, Mohammed and Hassany, Sahar and Zaghloul, Nariman and Magdy, Mai},
  title = {Efficacy and Safety of Levofloxacin‐ Versus Moxifloxacin‐Based Nitazoxanide Quadruple Therapy as Second‐Line Treatment for Helicobacter pylori in Egypt: A Randomized Multicenter Trial},
  journal = {Helicobacter},
  year = {2026},
  doi = {10.1111/hel.70104}
}
Kostenlos starten →